Comparison of the Additive Effects of Nipradilol and Carteolol to Latanoprost in Open-Angle Glaucoma

Abstract

Both nipradilol and carteolol have additive effects when used in combination with latanoprost. Carteolol, however, may have a more potent effect than nipradilol.

The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study

“…Haneda et al 18 report the additive effects of combining nipradilol to latanoprost at 4.8%, 18 with a mean IOP during latanoprost monotherapy of 16.8 mmHg, higher than that in the present study. To resolve such discrepancies, more cases need to be studied.…”

“…In the prior nipradilol group, the mean baseline IOP was 20.2 ± 3.1 mmHg, and this signifi cantly decreased to 16.7 ± 3.5 mmHg (17.1% decrease) during monotherapy (weeks [4][5][6][7][8][9][10][11][12]. Again, during combination therapy (weeks [16][17][18][19][20][21][22][23][24], the mean IOP decreased to 14.3 ± 3.1 mmHg (28.1% decrease from baseline), a signifi cant reduction in IOP, with a further decrease of 2.5 ± 1.5 mmHg (15.0%) over monotherapy.…”

“…That mean IOP significantly decreased to 14.9 ± 2.4 mmHg (23.7% decrease) during monotherapy (weeks [4][5][6][7][8][9][10][11][12]. During combination therapy (weeks [16][17][18][19][20][21][22][23][24], the mean IOP decreased even further, to 13.8 ± 1.9 mmHg (29.0% decrease from baseline), a signifi cant reduction in IOP, with a further decrease of 1.2 ± 1.1 mmHg (6.5%) over monotherapy. In the prior nipradilol group, the mean baseline IOP was 20.2 ± 3.1 mmHg, and this signifi cantly decreased to 16.7 ± 3.5 mmHg (17.1% decrease) during monotherapy (weeks [4][5][6][7][8][9][10][11][12].…”

“…Although the pharmacological differences in the ways latanoprost and nipradilol work to lower IOP may provide a more effective outcome when used as a combination, to the best of our knowledge, only a single prospective study has investigated the combined effects of latanoprost and nipradilol, 18 and no studies have examined either the safety of this combined therapy or the optimal dosage of drug administration.…”